{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T11:30:47Z","timestamp":1783769447486,"version":"3.55.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Many individuals with vitiligo are uncertain about their skin cancer risk, phototherapy risks, and recommended sun protective practices. This study examined the perceived skin cancer risk and sun protective practices among individuals living with vitiligo. A secondary objective was to understand where participants obtain this information. This was a prospective cross-sectional study. An online survey was distributed to vitiligo support group leaders globally who shared the survey with their members. Individuals over the age of 18 and with vitiligo were included. There were 209 survey respondents, the majority were between the ages 35\u201354 (45.5%, <jats:italic>n<\/jats:italic>\u2009=\u200995), female (70.8%, <jats:italic>n<\/jats:italic>\u2009=\u2009148), White (66.0%, <jats:italic>n<\/jats:italic>\u2009=\u2009138). Nearly half of respondents believed they were at increased risk of skin cancer because of their vitiligo (45.5%, <jats:italic>n<\/jats:italic>\u2009=\u200995) and nearly a quarter (22.5%, <jats:italic>n<\/jats:italic>\u2009=\u200947) believed that phototherapy increased their risk of skin cancer. Having vitiligo affected sun protective practices with less than a quarter (24.4%, <jats:italic>n<\/jats:italic>\u2009=\u200951) of respondents using sunscreen daily or often prior to their vitiligo diagnosis in comparison to the majority of respondents (60.3%, <jats:italic>n<\/jats:italic>\u2009=\u2009126) using it after their vitiligo diagnosis. The three most common sources where patients obtained information were the internet and social media (46.4%, <jats:italic>n<\/jats:italic>\u2009=\u200997), vitiligo support groups (23.4%, <jats:italic>n<\/jats:italic>\u2009=\u200949), and dermatologists (20.6%, <jats:italic>n<\/jats:italic>\u2009=\u200943). Despite evidence indicating a decreased risk of skin cancer in individuals with vitiligo and supporting the safety of narrowband ultraviolet B phototherapy, many participants believed they were at an increased risk of skin cancer. Findings were sub-stratified and showed differences in sunscreen usage based on gender, skin color, and percent depigmentation. This study also found nearly half of respondents obtained information related to vitiligo from the internet and social media. The number of participants may limit the generalizability of the findings. Survey questionnaires are also subject to response bias. The findings from this study highlight demographic variations in sunscreen usage which may help guide the development of targeted interventions to improve sun protective behaviors among diverse populations with vitiligo. In addition, this study suggests certain sun protective practices and skin cancer risk perceptions may vary based on extent of depigmentation. Lastly, this study also demonstrates the internet and social media as a popular source for obtaining information, emphasizing the need for dermatologists to leverage various online communication channels to help disseminate accurate information.<\/jats:p>","DOI":"10.1007\/s00403-024-02942-0","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:02:06Z","timestamp":1716390126000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Perception of skin cancer risk and sun protective practices in individuals with vitiligo: a prospective international cross-sectional survey"],"prefix":"10.1007","volume":"316","author":[{"given":"Sarah","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arielle Carolina","family":"Mora Hurtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole C.","family":"Syder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Rodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5956-4404","authenticated-orcid":false,"given":"Nada","family":"Elbuluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"issue":"2","key":"2942_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.det.2016.11.003","volume":"35","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues M (2017) Skin cancer risk (nonmelanoma skin cancers\/melanoma) in vitiligo patients. Dermatol Clin 35(2):129\u2013134. https:\/\/doi.org\/10.1016\/j.det.2016.11.003","journal-title":"Dermatol Clin"},{"issue":"1","key":"2942_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/bjd.12111","volume":"168","author":"HE Teulings","year":"2013","unstructured":"Teulings HE, Overkamp M, Ceylan E et al (2013) Decreased risk of melanoma and nonmelanoma skin cancer in patients with vitiligo: a survey among 1307 patients and their partners. Br J Dermatol 168(1):162\u2013171. https:\/\/doi.org\/10.1111\/bjd.12111","journal-title":"Br J Dermatol"},{"issue":"6","key":"2942_CR3","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.jaad.2014.07.050","volume":"71","author":"A Paradisi","year":"2014","unstructured":"Paradisi A, Tabolli S, Didona B, Sobrino L, Russo N, Abeni D (2014) Markedly reduced incidence of melanoma and nonmelanoma skin cancer in a nonconcurrent cohort of 10,040 patients with vitiligo. J Am Acad Dermatol 71(6):1110\u20131116. https:\/\/doi.org\/10.1016\/j.jaad.2014.07.050","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2942_CR4","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/pcmr.12161","volume":"26","author":"HP Naveh","year":"2013","unstructured":"Naveh HP, Rao UN, Butterfield LH (2013) Melanoma-associated leukoderma\u2014immunology in black and white? Pigment Cell Melanoma Res 26(6):796\u2013804. https:\/\/doi.org\/10.1111\/pcmr.12161","journal-title":"Pigment Cell Melanoma Res"},{"issue":"11","key":"2942_CR5","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.jid.2023.04.013","volume":"143","author":"J Ferguson","year":"2023","unstructured":"Ferguson J, Eleftheriadou V, Nesnas J (2023) Risk of melanoma and nonmelanoma skin cancer in people with vitiligo: United Kingdom population-based cohort study. J Invest Dermatol 143(11):2204\u20132210. https:\/\/doi.org\/10.1016\/j.jid.2023.04.013","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2942_CR6","first-page":"7","volume":"29","author":"LB Sel\u00e7uk","year":"2020","unstructured":"Sel\u00e7uk LB, Katkat E, Ar\u0131ca DA, Yayl\u0131 S, Bahad\u0131r S (2020) Sun-protection habits and knowledge of patients with vitiligo. Acta Dermatovenerol Alp Pannonica Adriat 29(1):7\u201310","journal-title":"Acta Dermatovenerol Alp Pannonica Adriat"},{"issue":"4","key":"2942_CR7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/ajd.12799","volume":"59","author":"PB McDonald","year":"2018","unstructured":"McDonald PB, Zapata L, Rodrigues M (2018) Sunscreen habits and skin cancer rates in patients with vitiligo in Australia. Australas J Dermatol 59(4):346\u2013348. https:\/\/doi.org\/10.1111\/ajd.12799","journal-title":"Australas J Dermatol"},{"issue":"3","key":"2942_CR8","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1111\/jdv.15264","volume":"33","author":"B Bhatia","year":"2019","unstructured":"Bhatia B, Kechichian E, Eleftheriadou V et al (2019) Habits and risk perception associated with sun exposure in vitiligo patients according to their participation in a patients\u2019 organization. J Eur Acad Dermatol Venereol 33(3):e100\u2013e103. https:\/\/doi.org\/10.1111\/jdv.15264","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2942_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","volume":"77","author":"M Rodrigues","year":"2017","unstructured":"Rodrigues M, Ezzedine K, Hamzavi I, Pandya AG, Harris JE, Vitiligo WG (2017) New discoveries in the pathogenesis and classification of vitiligo. J Am Acad Dermatol 77(1):1\u201313. https:\/\/doi.org\/10.1016\/j.jaad.2016.10.048","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2942_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamadermatol.2020.0218","volume":"156","author":"JM Bae","year":"2020","unstructured":"Bae JM, Ju HJ, Lee RW et al (2020) Evaluation for skin cancer and precancer in patients with vitiligo treated with long-term narrowband UV-B phototherapy. JAMA Dermatol 156(5):529\u2013537. https:\/\/doi.org\/10.1001\/jamadermatol.2020.0218","journal-title":"JAMA Dermatol"},{"issue":"4","key":"2942_CR11","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/bjd.18247","volume":"182","author":"HS Kim","year":"2020","unstructured":"Kim HS, Kim HJ, Hong ES et al (2020) The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population-based matched cohort study in Korea. Br J Dermatol 182(4):907\u2013915. https:\/\/doi.org\/10.1111\/bjd.18247","journal-title":"Br J Dermatol"},{"issue":"4","key":"2942_CR12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/ced.15010","volume":"47","author":"YH Wu","year":"2022","unstructured":"Wu YH, Chou CL, Chang HC (2022) Risk of skin cancer after ultraviolet phototherapy in patients with vitiligo: a systematic review and meta-analysis. Clin Exp Dermatol 47(4):692\u2013699. https:\/\/doi.org\/10.1111\/ced.15010","journal-title":"Clin Exp Dermatol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-024-02942-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-024-02942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T09:51:33Z","timestamp":1717494693000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-024-02942-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":12,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["2942"],"URL":"https:\/\/doi.org\/10.1007\/s00403-024-02942-0","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"1 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Elbuluk has served as a consultant, advisory board member, and\/or speaker for Avita, Scientis, Incyte, VisualDx, La Roche Posay, Beiersdorf, Unilever, Allergan, Eli Lilly, Galderma, Pfizer, Janssen, La Roche Posay, L\u2019Oreal, McGraw Hill, Dior, Medscape. She has received royalties from McGraw-Hill. She has served as an investigator for Avita and has stock options in VisualDx. The other authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}],"article-number":"189"}}